A Necroptosis-Related Seven-Gene Risk Score Stratifies Prognosis and Predicts Immunotherapy Response and EGFR-TKI Sensitivity in Lung Adenocarcinoma

Background Necroptosis is a regulated form of inflammatory cell death with context-dependent roles in tumor progression and immune regulation. However, the prognostic value and therapeutic implicati 1 Introduction Lung cancer remains the leading cause of cancer-related death worldwide, accounting for...

Federica Pecci: Predictors of Early Progression on First-Line Osimertinib in EGFR-Mutant NSCLC

Federica Pecci: Predictors of Early Progression on First-Line Osimertinib in EGFR-Mutant NSCLC “Glad to share our manuscript just published in JTO investigating the clinicogenomic determinants of earlier progression with osimertinib monotherapy in EGFR-mutant NSCLC. To study early osimertinib progression further,...

New Drug Application Submission Completed for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

This is a paid press release. Contact the press release distributor directly with any inquiries. New Drug Application Submission Completed for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer Cullinan Therapeutics, Inc. Thu, November...

Small-cell lung cancer transformation approximately four years after surgery and adjuvant therapy for EGFR-mutant lung adenocarcinoma: a case report

BackgroundTransformation of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) to small-cell lung cancer (SCLC) is a recognize 2 Case description2.1 Patient information and initial diagnosis A 48-year-old female presented to a local hospital in February 2014 with...

Long-Term Recurrence-Free Survival After Surgery and Adjuvant Furmonertinib in a Patient With EGFR-Mutated Pulmonary Sarcomatoid Carcinoma: A Case Report

Background Pulmonary sarcomatoid carcinoma (PSC) is an extremely rare subtype of non-small cell lung cancer (NSCLC), which generally shows limited response to chemoradiotherapy and confers poor over 1 Introduction Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small cell...

Osimertinib, platinum, and etoposide for patients with metastatic EGFR/TP53/RB1-mutant lung cancers at risk for histological transformation

AbstractAlthough EGFR inhibitors are highly effective for treating EGFR-mutant lung adenocarcinomas (EGFR+ LUADs), resistance inevitably emerges, with histologic transformation to small cell lung cancer (SCLC) representing a particularly aggressive mechanism. Our prospective trial enrolled patients with EGFR+ LUAD at high...